
THE PATHFINDER **STUD**

Assessment of the Implementation of an Investigational Multi-Cancer Early Detection **Test Into Clinical Practice**

GRAIL

The PATHFINDER Study is an interventional, multi-center study that evaluated GRAIL's multi-cancer early detection blood test Galleri™ in a clinical setting. The study marked the first time the test was used to return results to healthcare providers and participants to help guide the appropriate diagnostic workup for 50+ cancer types.



Study Findings

The first PATHFINDER results demonstrating Galleri's performance in a clinical setting are consistent with findings from previous observational studies. These results include that Galleri can detect multiple types of cancers in their early stages with a high positive predictive value, and determine where in the body the cancer signal is located with high accuracy.

13 types of cancer including:

- Breast
- Colon or rectum
- Head and neck
- Liver & bile duct Lung
- 29
- cancers found

23 new cancers: 40% detected while still localized (I-II) and more than half before distant metastases (I-III) Where stage was available

95%

- Lymphoid Leukemia
- Lymphoma Ovary
- Pancreas
- Plasma cell Neoplasm

96.3% 44.6% accuracy in predicting the cancer signal

of origin

were Likely or Very Likely to follow healthcare provider's cancer

screening recommendations

Participant attitudes indicate continued

adherence toward recommended screenings:

Prostate

Small intestine

macroglobulinemia

Waldenstrom

positive predictive value

High satisfaction among PATHFINDER participants was recorded:

Satisfied, Very or Extremely Satisfied with the 97% multi-cancer early detection test

Very or Extremely Confident that "this multi-cancer early detection test is a good thing for you" 83%